Yiwei Guo

Harbin, 150081, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Mechanism of METTL3 promoting rituximab resistance via β-catenin/MYC axis in double-expressor diffuse large B cell lymphoma.

Mechanism of METTL3 promoting rituximab resistance via β-catenin/MYC axis in double-expressor diffuse large B cell lymphoma.

Journal: Pathology, research and practice

Published: February 03, 2026

HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.

HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.

Journal: Journal of proteome research

Published: November 24, 2025

Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.

Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.

Journal: Hematology (Amsterdam, Netherlands)

Published: December 26, 2024

Prognostic marker CD27 and its micro-environmental in multiple myeloma.

Prognostic marker CD27 and its micro-environmental in multiple myeloma.

Journal: BMC cancer

Published: December 16, 2023

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.

Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.

Journal: Autoimmunity

Published: September 22, 2023

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.

Journal: PeerJ

Published: August 21, 2023

Correction: HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

Correction: HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

Journal: Journal of translational medicine

Published: January 31, 2023

Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators.

Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International Prognostic Index scores and clinical indicators.

Journal: Annals of translational medicine

Published: November 15, 2022

HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.

Journal: Journal of translational medicine

Published: September 12, 2022

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.

Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.

Journal: Journal of proteome research

Published: March 02, 2021

Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.

Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.

Journal: Biochemical and biophysical research communications

Published: September 13, 2018

BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.

BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.

Journal: Experimental hematology

Published: September 30, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026